Abstract
Amyloid fibril formation of amyloid beta peptide 1-40 (Aβ 1-40) was reported to be retarded in the presence of 150mM phosphate buffer at pH 7 [Monji, Ustumi, Ueda, Imoto, Yoshida, Hashioka, Tashiro and Tashiro, J. Neurochemistry, 77, 1425-1432 (2007)]. In order to elucidate the reason why phosphate ion retards the amyloid fibril formation, we examined the preferential binding sites of phosphate ion to Aβ 1-40 using chemical shift perturbation analysis of heteronuclear NMR. In titration analysis of 15N-labeled Aβ1-40 in the presence of 150 mM phosphate ion or 150 mM chloride ion, we identified the residues affected by these ions in Aβ 1-40. As a result, we found the tendency that phosphate ion preferentially bound to some residues located on the C-terminus region where the region was reported to be the potential β-strand region in Aβ1-40. Therefore, we suggested that phosphate ions interacted with the potential β-strand region in Aβ1-40 to be hard to form β-sheet in Aβ 1-40, resulting in retardation of the amyloid fibril formation.
Keywords: Alzheimer's disease, amyloid beta peptide 1-40, chemical shift perturbation analysis, heteronuclear NMR, phosphate ion
Protein & Peptide Letters
Title: Evidence for the Binding of Phosphate Ion to the C-Terminus Region in Aβ1-40 Using Heteronuclear NMR Analyses
Volume: 17 Issue: 2
Author(s): Makiko Nagata-Uchiyama, Yoshito Abe, Akira Monji, Shigenobu Kanba and Tadashi Ueda
Affiliation:
Keywords: Alzheimer's disease, amyloid beta peptide 1-40, chemical shift perturbation analysis, heteronuclear NMR, phosphate ion
Abstract: Amyloid fibril formation of amyloid beta peptide 1-40 (Aβ 1-40) was reported to be retarded in the presence of 150mM phosphate buffer at pH 7 [Monji, Ustumi, Ueda, Imoto, Yoshida, Hashioka, Tashiro and Tashiro, J. Neurochemistry, 77, 1425-1432 (2007)]. In order to elucidate the reason why phosphate ion retards the amyloid fibril formation, we examined the preferential binding sites of phosphate ion to Aβ 1-40 using chemical shift perturbation analysis of heteronuclear NMR. In titration analysis of 15N-labeled Aβ1-40 in the presence of 150 mM phosphate ion or 150 mM chloride ion, we identified the residues affected by these ions in Aβ 1-40. As a result, we found the tendency that phosphate ion preferentially bound to some residues located on the C-terminus region where the region was reported to be the potential β-strand region in Aβ1-40. Therefore, we suggested that phosphate ions interacted with the potential β-strand region in Aβ1-40 to be hard to form β-sheet in Aβ 1-40, resulting in retardation of the amyloid fibril formation.
Export Options
About this article
Cite this article as:
Nagata-Uchiyama Makiko, Abe Yoshito, Monji Akira, Kanba Shigenobu and Ueda Tadashi, Evidence for the Binding of Phosphate Ion to the C-Terminus Region in Aβ1-40 Using Heteronuclear NMR Analyses, Protein & Peptide Letters 2010; 17 (2) . https://dx.doi.org/10.2174/092986610790226058
DOI https://dx.doi.org/10.2174/092986610790226058 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
Call for Papers in Thematic Issues
Therapeutic Proteins and Peptides of Plant Origin
Plants are still the major repository of biologically active substances. In the last two decades, however, natural peptides and proteins of plant origin have gained increasing attention due to their pharmacological activities over a variety of human illnesses, including those mediated by infections and parasitosis and those involving different cellular ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
In Silico ADME and QSAR Studies on a Set of Coumarin Derivatives As Acetylcholinesterase Inhibitors Against Alzheimer’s Disease: CoMFA, CoMSIA, Topomer CoMFA, and HQSAR
Letters in Drug Design & Discovery 4-methylamphetamine (4-MA): Chemistry, Pharmacology and Toxicology of a New Potential Recreational Drug
Mini-Reviews in Medicinal Chemistry Utilising Nanotechnology and Nanosystems for Treatment of Rare Diseases
Pharmaceutical Nanotechnology Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Enantiomeric Profiling of Chiral Pharmacologically Active Compounds in the Environment with the Usage of Chiral Liquid Chromatography Coupled with Tandem Mass Spectrometry
Current Analytical Chemistry Cytoprotection by Melatonin, Precursors and Metabolites in an In Vitro Model of Neurotoxicity Induced by Okadaic Acid
Letters in Drug Design & Discovery Dual Targeting of Glioma U251 Cells with Nanoparticles Prevents Tumor Angiogenesis and Inhibits Tumor Growth
Current Neurovascular Research Therapeutic Interventions Targeting Beta Amyloid Pathogenesis in an Aging Dog Model
Current Neuropharmacology Regulatory Aspects of Post-Approval Safety Reporting for Generic Drug Products in the US
Applied Clinical Research, Clinical Trials and Regulatory Affairs Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Role of T Lymphocytes in the Development of Rheumatoid Arthritis. Implications for Treatment
Current Pharmaceutical Design Nephroprotective Potential of Urtica parviflora Roxb. Against Paracetamol Induced Nephrotoxicity in Rats
The Natural Products Journal The Impact of Diabetes on Adolescent Development: The Experiences of Teenagers with Diabetes Attending a Summer Camp
Adolescent Psychiatry The New Compound GET73, N-[(4-trifluoromethyl)benzyl]4-methoxybutyramide, Regulates Hippocampal Aminoacidergic Transmission Possibly Via an Allosteric Modulation of mGlu5 Receptor. Behavioural Evidence of its “Anti-Alcohol” and Anxiolytic Properties
Current Medicinal Chemistry Prevalence of Anxiety, Depression, Sleep Disturbance, Fibromyalgia, Obesity, and Gastroesophageal Disease in Patients with Rheumatic Diseases
Current Rheumatology Reviews A New Schizophrenia Model: Immune Activation is Associated with the Induction of Different Neurotoxic Products which Together Determine Memory Impairments and Schizophrenia Symptom Dimensions
CNS & Neurological Disorders - Drug Targets Topical Capsaicin for the Treatment of Neuropathic Pain
Current Drug Metabolism Neuroprotective Effects of Nonsteroidal Anti-inflammatory Drugs on Neurodegenerative Diseases
Current Pharmaceutical Design Strategies to Reduce Oxidative Stress in Glaucoma Patients
Current Neuropharmacology Relevance of the Chronobiological and Non-chronobiological Actions of Melatonin for Enhancing Therapeutic Efficacy in Neurodegenerative Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)